

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Karl-Hermann SCHLINGENSIEPEN	Group Art Unit:	1637
Serial No.:	10/591,048	Confirmation No.	4668
Date Filed:	03/28/2007	Examiner:	Gary Benzion
For:	PHARMACEUTICAL COMPOSITION		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-450

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted today via the Office electronic filing system (EFS-Web) in accordance with 37 CFR „§1.8.

Date: 01/18/2011

Signature: /Diane Taylor/

Printed Name: Diane Taylor

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, it is respectfully requested that the references listed on the accompanying enclosed Form PTO/SB/08a be made of record and considered with respect to the above-referenced U.S. patent application. A copy of any foreign references and non-patent literature is enclosed.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability, or that the information is analogous to the subject matter of the present invention, or that no other material information exists. Further, the filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner. Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.

This Supplemental Information Disclosure Statement is filed after the first office action on the merits, but before a final office action or notice of allowance. In accordance with 37 C.F.R. 1.97(c), this paper is accompanied by payment of the \$180 fee. If any additional fee is due, the Commissioner is hereby authorized to charge any deficiency in fees to Deposit Account No. 14-1437.

In order to facilitate the resolution of any issues or questions presented by this paper, the Examiner may directly contact the undersigned by phone to further the discussion.

Novak Druce + Quigg LLP  
City Place Tower  
525 Okeechobee Blvd.  
Fifteenth Floor  
West Palm Beach, FL 33401  
Telephone: (561) 847-7809  
Facsimile: (561) 847-7801  
[amy.dobbelaere@novakdruce.com](mailto:amy.dobbelaere@novakdruce.com)

Respectfully submitted,

/Amy Dobbelaere/

Amy A. Dobbelaere, Ph.D.  
Reg. No. 52,088